List of Excipients in Branded Drug ASCLERA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merz North America Inc	ASCLERA	polidocanol	46783-221	ALCOHOL
Merz North America Inc	ASCLERA	polidocanol	46783-221	MONOBASIC POTASSIUM PHOSPHATE
Merz North America Inc	ASCLERA	polidocanol	46783-221	SODIUM PHOSPHATE, DIBASIC

ASCLERA Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Asclera is an FDA-approved polidocanol injection for sclerotherapy of uncomplicated spider veins and reticular veins. Its U.S. formulation is simple: polidocanol in an aqueous vehicle containing ethanol and tromethamine. The commercial opportunity is not based on discovering a new excipient. It lies in improving presentation, container closure, administration workflow, manufacturing reliability, and differentiated polidocanol delivery systems.

Asclera contains no biologic active ingredient and therefore has no biosimilar pathway. Generic entry would proceed through an abbreviated new drug application, with formulation, pharmaceutical-equivalence, bioequivalence, and labeling requirements determining the principal barriers.

What is the Asclera formulation and which excipients does it contain?

Asclera is supplied in 0.5% and 1% strengths. The active ingredient is polidocanol, also known as lauromacrogol 400. The labeled inactive ingredients are ethanol, tromethamine, and water for injection.[1]

Component	Function in Asclera	Commercial and technical relevance
Polidocanol	Sclerosant active ingredient	Determines concentration, local tolerability, and clinical performance
Ethanol	Co-solvent and formulation aid	Supports solubility; creates flammability, evaporation, and container-closure considerations
Tromethamine	Buffering agent and pH control	Helps maintain formulation pH and may influence stability and injection tolerability
Water for injection	Aqueous vehicle	Requires sterile manufacturing and control of endotoxin, particulate, and bioburden risks

The formulation is a sterile injectable solution rather than a suspension, emulsion, liposome, or biologic. This limits the value of complex excipient systems. A new product must improve a commercially relevant attribute without changing polidocanol exposure, local tolerability, sclerosant activity, or administration technique.

What excipient functions matter most for polidocanol injection?

The highest-value functions are:

1. Maintaining polidocanol solubility at the labeled concentrations.
2. Controlling pH and minimizing injection-site discomfort.
3. Preserving sterility without relying on antimicrobial preservatives.
4. Limiting adsorption, leachables, and extractables from the container.
5. Supporting a reproducible fill-finish process.
6. Enabling a differentiated delivery format, such as a prefilled syringe or foam system.

Because Asclera is administered directly into veins, excipient selection has a narrower safety margin than in many oral products. New surfactants, co-solvents, preservatives, or viscosity modifiers would require a strong justification and targeted local-tolerability data.

What FDA regulatory status and exclusivity apply to Asclera?

Asclera was approved by the FDA on March 30, 2010, under NDA 021201. The labeled indication covers uncomplicated spider veins and reticular veins of the lower extremity.[1]

Regulatory item	Asclera status
Active ingredient	Polidocanol
Dosage form	Sterile injection
U.S. strengths	0.5% and 1%
Application type	NDA
NDA number	021201
Original FDA approval	March 30, 2010
Biosimilar pathway	Not applicable
Likely generic pathway	ANDA
FDA exclusivity	Original approval exclusivity has expired
Patent-centered commercial protection	No meaningful remaining composition-of-matter protection for polidocanol

The product is a small-molecule injectable. FDA approval does not confer biologic exclusivity, and a follow-on product would not be classified as a biosimilar. The main competitive route is an ANDA referencing the listed drug.

Current Orange Book status must be evaluated using the active FDA listing because patent listings and marketing status can change. The commercial significance of any listed patent would depend on whether it covers the approved product, a specific formulation, a method of use, or a device-linked presentation.[2]

When does Asclera lose exclusivity and when can generic polidocanol launch?

Asclera’s original regulatory exclusivity has expired. Any future generic launch depends primarily on:

• FDA approval of an ANDA;
• resolution of any listed-patent certifications;
• certification of pharmaceutical equivalence;
• demonstration of bioequivalence or an FDA-accepted alternative;
• compliance with injectable manufacturing requirements;
• commercial readiness of sterile fill-finish capacity.

For a generic polidocanol injection, the most relevant certification would be a Paragraph IV certification if an applicant alleges that an Orange Book-listed patent is invalid, unenforceable, or not infringed. A Paragraph IV notice could trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework, subject to statutory conditions.[3]

What generic entry risks exist for Asclera?

Generic risk is structurally high because:

• the active ingredient is a known small molecule;
• the formulation is relatively simple;
• the product has no biologic exclusivity;
• the indication is narrow and well defined;
• the dosage form is a conventional sterile injection;
• excipient complexity is limited.

The principal barriers are not molecular discovery. They are sterile manufacturing, product quality, container-closure performance, clinical comparability, supply reliability, and physician adoption.

What patents protect Asclera and its excipient formulation?

Polidocanol’s basic composition-of-matter protection is long expired. Any residual patent value would more likely reside in:

• specific concentrations;
• injection protocols;
• treatment of defined venous conditions;
• foam formulations;
• foam-generation systems;
• container or delivery devices;
• manufacturing and sterilization processes;
• combination products.

A patent directed only to the use of polidocanol for a covered indication may not block every generic product. Its value depends on the label sought by the ANDA applicant and the scope of any use code. A generic applicant may pursue a label that omits a patented method of use if FDA requirements permit a valid “skinny label.”

How strong is the remaining patent estate?

The estate is likely weak for the basic liquid injection and stronger for differentiated delivery systems. The strongest commercial claims would typically attach to:

Patent subject	Relative strategic strength	Reason
Polidocanol molecule	Low	Historical composition protection has expired
Basic aqueous injection	Low to moderate	Easy to design around unless narrowly claimed
Specific pH or excipient ratio	Moderate	Can create formulation distinctions but may face obviousness challenges
Prefilled syringe or specialized container	Moderate	Can protect workflow and packaging if technically specific
Polidocanol foam	Moderate to strong	May involve formulation, gas phase, device, and process claims
Automated foam-generation device	Stronger	Device and process claims can create practical switching costs
Manufacturing process	Moderate	Valuable if it improves sterility, stability, or reproducibility
Treatment protocol	Variable	Depends on claim scope and label strategy

A durable patent strategy would combine formulation claims with device, packaging, manufacturing, and method-of-use claims. A single narrow excipient claim would provide limited protection against a generic developer using an alternate buffer or co-solvent.

What formulations are protected or commercially available for polidocanol?

The principal formulation categories are liquid polidocanol injection and polidocanol microfoam.

Liquid polidocanol injection

Asclera is a ready-to-use liquid injection in 0.5% and 1% strengths. This format is operationally simple and suitable for outpatient use. Its limitations include the need for manual administration, restricted differentiation, and exposure to generic substitution.

Polidocanol microfoam

Varithena is a separate FDA-approved polidocanol product using a proprietary foam delivery system for treatment of incompetent veins.[4] It demonstrates that the commercial value of polidocanol can shift from the active ingredient to the delivery platform.

A foam product cannot be treated as a routine excipient substitution. Foam properties depend on gas selection, surfactant behavior, bubble-size distribution, persistence, preparation method, and administration equipment. A foam platform may require a new drug application or another substantial regulatory pathway rather than a straightforward generic application.

Preservative-free unit-dose formats

A preservative-free, single-use vial or prefilled syringe could improve handling and reduce preparation steps. The opportunity is strongest where the product can:

• reduce dosing errors;
• limit vial waste;
• shorten procedure time;
• improve sterility assurance;
• support predictable delivery volumes;
• integrate with a clinician’s injection workflow.

The primary technical work would involve syringe compatibility, silicone oil, stopper and plunger materials, extractables, leachables, particulate control, and stability over the proposed shelf life.

Which excipient strategies offer the best commercial opportunity?

1. Optimize the existing ethanol-tromethamine system

The lowest-risk strategy is to preserve the basic composition while tightening control of:

• ethanol concentration;
• pH range;
• osmolality;
• particulate burden;
• degradation products;
• container-closure interaction.

This approach could support a generic product or a supply agreement without creating a strong product-differentiation position. Its value is primarily manufacturing and quality related.

2. Develop a prefilled syringe

A prefilled syringe could create a more visible commercial distinction than a minor excipient change. Relevant development issues include:

• compatibility with ethanol-containing solutions;
• plunger and stopper extractables;
• silicone-related particulates;
• needle gauge and injection force;
• fill volume accuracy;
• terminal sterilization versus aseptic processing;
• storage orientation and shipping robustness.

A prefilled presentation may support premium pricing, but it would face competition from lower-cost vials unless it produces measurable workflow savings.

3. Create a lower-irritancy formulation

A reformulated product could target injection discomfort or local tolerability through changes in pH, buffer concentration, ethanol level, or tonicity. This is commercially attractive but technically difficult. Lowering ethanol or changing the buffer may reduce solubility or alter polidocanol’s local activity.

Any tolerability claim would require controlled comparative evidence. Without clinical evidence, a new excipient composition would be difficult to distinguish from a generic formulation.

4. Develop polidocanol foam

Foam is the highest-value formulation opportunity but also the highest-regulatory-risk strategy. Potentially protectable elements include:

• bubble-size distribution;
• foam half-life;
• gas-liquid ratio;
• preparation device;
• mixing protocol;
• administration catheter;
• storage and use conditions.

The commercial benchmark is Varithena, which shows that polidocanol delivery technology can support a separate branded product.[4] A competing platform would need a clear clinical, procedural, or economic advantage.

5. Build a formulation and device platform

The strongest long-term strategy would combine:

• a stable polidocanol formulation;
• a proprietary container;
• a controlled administration device;
• a defined procedural protocol;
• manufacturing claims covering reproducible product attributes.

This creates a broader intellectual-property estate than an excipient-only patent and raises switching costs for clinics.

What manufacturing and IP barriers affect commercial entry?

Sterile injectable manufacturing is the main operational barrier. A new entrant must control:

• aseptic processing;
• endotoxin and sterility specifications;
• visible and subvisible particles;
• ethanol concentration during filling;
• container closure integrity;
• extractables and leachables;
• stability under temperature excursions;
• supply of pharmaceutical-grade tromethamine and ethanol.

Ethanol creates a specific process concern because it is volatile. Filling, storage, and container closure must prevent concentration drift. Material compatibility is also important because ethanol can interact with elastomers, adhesives, coatings, and certain polymer components.

The IP barrier is lower for a conventional liquid injection and higher for foam or device-based products. Manufacturing know-how can still create an effective commercial barrier even where patent protection is limited.

Which companies are challenging Asclera and what is the competitive landscape?

The competitive landscape has three levels.

Competitive segment	Representative products or companies	Competitive basis
Liquid polidocanol	Asclera and potential ANDA applicants	Price, availability, vial size, supply reliability
Polidocanol foam	Varithena, marketed by BTG/Teleflex	Delivery technology and treatment of incompetent veins
Alternative sclerosants	Sodium tetradecyl sulfate products and other sclerosants	Physician preference, indication, cost, and tolerability

Asclera’s direct generic threat is more significant than biosimilar risk because polidocanol is a small molecule. Varithena is a product-level competitor rather than a direct generic equivalent because its delivery system and clinical positioning differ from conventional Asclera injection.[4]

No biosimilar competition is relevant. Paragraph IV activity, if initiated, would be the most important patent-litigation trigger for the liquid product. A separate dispute involving foam or device patents would affect a different product category.

What licensing and partnering opportunities exist for Asclera?

The most credible licensing opportunities are formulation and delivery partnerships rather than licensing the polidocanol molecule itself.

Potential deal structures include:

• licensing a prefilled-syringe platform to the product owner;
• supplying a validated ethanol-compatible container closure;
• co-developing a foam-generation device;
• licensing a sterile fill-finish process;
• granting regional rights for a generic polidocanol injection;
• partnering with a specialty pharmaceutical company for vascular-clinic distribution.

A formulation supplier should seek claims covering measurable product attributes, such as stability, particulate control, foam persistence, or injection performance. A supply agreement based only on commodity ethanol or tromethamine would have limited negotiating leverage.

How should revenue exposure and launch scenarios be modeled?

Public disclosures do not establish a reliable standalone Asclera revenue figure. Revenue exposure should therefore be modeled through scenarios rather than an assumed product-level number.

Scenario	Expected effect
No approved generic	Maintains branded pricing and current presentation economics
One generic entrant	Creates price pressure and potential channel substitution
Multiple ANDA entrants	Accelerates price erosion and increases supply competition
Premium prefilled syringe	May preserve margin if workflow savings justify a premium
Successful foam platform	Can shift revenue from commodity injection volume to differentiated procedure economics
Supply disruption	Creates temporary opportunity for alternate manufacturers and CDMOs

For an excipient or packaging company, the addressable opportunity is likely greater in recurring component supply, sterile fill-finish, and device integration than in licensing a new chemical excipient.

Key Takeaways

• Asclera is a sterile polidocanol injection containing ethanol, tromethamine, and water for injection.
• Original regulatory exclusivity has expired, and biosimilar competition is not relevant.
• Generic entry risk is high for the conventional liquid injection.
• The basic excipient system offers limited standalone differentiation.
• The strongest opportunities are prefilled syringes, preservative-free unit-dose formats, foam delivery, and container-closure systems.
• Foam and device combinations offer stronger patent potential than a simple reformulation.
• Ethanol volatility, extractables, leachables, particulate control, and sterile fill-finish are key technical barriers.
• Varithena is the principal branded benchmark for differentiated polidocanol delivery.
• Licensing value is highest in delivery systems, packaging, manufacturing, and procedural platforms.
• A sustainable commercial strategy should combine formulation, device, manufacturing, and method-of-use claims.

FAQs

Is Asclera a biologic or a small-molecule drug?

Asclera is a small-molecule drug product containing polidocanol. It is not eligible for a biosimilar approval pathway.

Can a generic manufacturer use different excipients from Asclera?

A generic applicant may use different inactive ingredients if FDA requirements for pharmaceutical equivalence, safety, quality, and bioequivalence are satisfied. A material change in excipient composition can increase regulatory and clinical comparability requirements.

Does ethanol in Asclera create formulation or packaging risk?

Yes. Ethanol can affect solubility, concentration stability, elastomers, adhesives, and extractables. Container-closure integrity and fill-volume control are important development issues.

Is polidocanol foam a generic version of Asclera?

Not necessarily. A polidocanol foam product may involve different formulation attributes, delivery equipment, clinical use, and regulatory requirements. Varithena is an example of a differentiated polidocanol foam product rather than a conventional liquid-injection equivalent.

What is the most defensible IP strategy for a new polidocanol product?

The strongest strategy generally combines formulation claims with device, container, manufacturing, foam-property, and method-of-use claims. An excipient-only patent is less likely to block design-around competition.

References

1. U.S. Food and Drug Administration. (2010). Asclera (polidocanol) injection prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process and Paragraph IV patent certifications.
4. U.S. Food and Drug Administration. (2013). Varithena (polidocanol) injectable foam prescribing information.